Hope Rugo, MD, breast oncologist at University of California, San Francisco, spoke about what we can look forward to in breast cancer treatment at the 37th Annual Miami Breast Cancer Conference, held from March 5-8, 2020 in Miami, Florida.
Transcription:
Well, I think there’s so many things going on. I mean, we’re really looking forward to the adjuvant data with CDK4/6 inhibitors we hope to see soon. We’re looking for event-free survival in the KEYNOTE-522 trial. More trials with immunotherapy so we understand it more in both within the adjuvant, neoadjuvant, and metastatic setting. We’re looking for sacituzumab govitecan (IMMU-132) to be approved this year in triple negative breast cancer. There’s an ongoing trial in hormone receptor positive disease called TROPICS which that is enrolling quickly and hopefully that will be another option as well, and then to rapidly…
